InsidersTradesSigma
Follow the Celularity Inc share price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Celularity Inc has recorded 113 insider filings. Market capitalisation: €19.9m. The latest transaction was reported on 15 April 2026 (Levée d'options). Among the most active insiders: Hariri Robert J. All data is free.
113
Insider Decl.
n/a
Thresholds
€6m
5 ops.
Buy Volume
n/a
1 ops.
Sell Volume
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 15 April 2026
Declarations113 total
821 shares0Class A Common StockSEC:0001493152-26-016834:0
1,641 shares0Class A Common StockSEC:0001493152-26-016833:0
3,281 shares0Class A Common StockSEC:0001493152-26-016832:0
30,000 shares0Class A Common StockSEC:0001493152-26-002427:0
20,385 shares0Class A Common StockSEC:0001493152-26-002425:0
19,231 shares0Class A Common StockSEC:0001493152-26-002424:0
28,847 shares0Class A Common StockSEC:0001493152-26-002423:0
19,231 shares0Class A Common StockSEC:0001493152-26-002303:0
28,847 shares0Class A Common StockSEC:0001493152-26-002300:0
20,385 shares0Class A Common StockSEC:0001493152-26-002298:0
30,000 shares0Class A Common StockSEC:0001493152-26-002297:0
125,000 shares0Class A Common StockSEC:0001493152-25-029618:0
125,000 shares0Class A Common StockSEC:0001493152-25-029615:0
125,000 shares0Class A Common StockSEC:0001493152-25-029617:0
125,000 shares0Class A Common StockSEC:0001493152-25-029614:0
67,416 shares0Class A Common StockSEC:0001493152-25-028787:0
67,416 shares0Class A Common StockSEC:0001493152-25-028780:0
67,416 shares0Class A Common StockSEC:0001493152-25-028778:0
61,539 shares0Class A Common StockSEC:0001493152-25-024634:0
3,699 shares0Class A Common StockSEC:0001493152-25-024633:0
44,379 shares0Class A Common StockSEC:0001493152-25-024631:0
47,042 shares0Class A Common StockSEC:0001493152-25-024630:0
3,281 shares0Class A Common StockSEC:0001641172-25-013629:0
360 shares@ US$1.642.4% of flowClass A Common StockSEC:0001641172-25-004820:1
577 shares@ US$1.642.4% of flowClass A Common StockSEC:0001641172-25-004822:1
25 of 113 declarations
关于 Celularity Inc
Celularity Inc.是一家生物技术和再生医学公司，在美国纳斯达克上市，股票代码为CELU。对于投资者而言，它最好被理解为一家投机性小型生物技术公司，其价值主张围绕胎盘衍生生物学构建。该公司现在将自己定位为一个专注于长寿的细胞医学平台，将临床阶段的细胞疗法开发与源自产后胎盘的商业生物材料业务相结合。（[celularity.com](https://celularity.com/celularity-announces-filing-of-form-10-k-regains-nasdaq-compliance-and-highlights-continued-strategic-transformation/?utm_source=openai)） 该公司的根源可追溯到1998年成立的Anthrogenesis，随后于2002年与Celgene合并，并于2017年分拆成立Celularity。Celularity于2021年成为一家上市公司。其目前的总部位于新泽西州弗洛勒姆帕克，尽管早期的公司材料也提及在设施开发早期阶段位于新泽西州沃伦。（[celularity.com](https://celularity.com/about/?utm_source=openai)） 在运营方面，Celularity围绕两大主要业务线构建。首先，它商业化或货币化用于伤口护理和组织修复应用的胎盘生物材料。其次，它开发源自产后胎盘的现成、冷冻保存的同种异体细胞疗法，包括自然杀伤（NK）细胞、工程T细胞（如CAR-T构建体）和间充质样基质细胞。该公司强调其集成的制造平台和占地150,000平方英尺的设施，专门用于转化研究和细胞医学生产。（[celularity.com](https://celularity.com/?utm_source=openai)） 从竞争角度来看，Celularity正试图通过可扩展的制造模式和即用型产品概念来区分自己，从而避免自体细胞疗法的一些物流复杂性。尽管如此，该公司在一个竞争激烈且资本密集的环境中运营，成功取决于临床验证、制造质量、监管执行和融资纪律。其开发项目针对肿瘤学、传染病、退行性疾病和衰老生物学，这使得机会范围广泛但也具有科学挑战性。（[celularity.com](https://celularity.com/?utm_source=openai)） 最近的公司发展表明了有意的战略调整。2026年5月，Celularity宣布已提交其Form 10-K，并在延迟提交后重新符合纳斯达克上市要求。该公司还与NexGel完成了一项交易，将部分生物材料产品组合货币化，达成了一项战略许可协议，该协议可能产生高达35 million美元的预付款和里程碑相关价值，并从出售未使用的New Jersey净经营亏损和研发税收抵免中获得了12.2 million美元。此外，它还完成了融资交易，以支持持续运营和战略举措。总而言之，这些举措表明该公司专注于增强流动性，优化其产品组合，并将资源集中于其以长寿为导向的治疗管线。（[celularity.com](https://celularity.com/celularity-announces-filing-of-form-10-k-regains-nasdaq-compliance-and-highlights-continued-strategic-transformation/?utm_source=openai)）
